Erlotinib (Multichem)

País: Nova Zelândia

Língua: inglês

Origem: Medsafe (Medicines Safety Authority)

Ingredientes ativos:

Erlotinib hydrochloride 163.9mg equivalent to erlotinib 150mg

Disponível em:

Multichem NZ Limited

Dosagem:

150 mg

Forma farmacêutica:

Film coated tablet

Composição:

Active: Erlotinib hydrochloride 163.9mg equivalent to erlotinib 150mg Excipient: Opadry White 20B58900 Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium laurilsulfate Sodium starch glycolate

Tipo de prescrição:

Prescription

Indicações terapêuticas:

· Erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with activating EGFR mutations. · Erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who have previously received chemotherapy.

Resumo do produto:

Package - Contents - Shelf Life: Blister pack, PVC/Al foil strips in cardboard carton - 30 tablets - 36 months from date of manufacture stored at or below 25°C

Data de autorização:

2020-04-15